EClinCloud Completes Tens of Millions of RMB in Series A Financing to Accelerate Its Clinical Evidence Support Platform

EClinCloud Technology Co., Ltd. ("EClinCloud") recently announced the completion of tens of millions of RMB in Series A financing, exclusively invested by Kangjun Capital.
The proceeds will primarily be used to further strengthen its R&D, medical, clinical operations, and clinical data science teams, accelerate the realization of a patient-centric integrated cloud platform, and enhance after-sales service capabilities. Through its intelligent cloud platform, it provides more reliable clinical trial endpoint assessment solutions. To date, EClinCloud's clinical evidence support cloud platform has taken initial shape, including eCOA, CTMS, eTMF, EDC, RTSM, Resource Management, and more.
EClinCloud is headquartered in Shenzhen Bay Eco-Technology Park, at the core of the Guangdong–Hong Kong–Macao Greater Bay Area, with an R&D center in Chengdu and offices in Beijing and Shanghai. Currently, EClinCloud has established partnerships with several leading innovative pharmaceutical companies and CRO companies. As the exclusive strategic partner of Signant Health in Greater China, EClinCloud leverages top international expert resources to continuously expand its businesses in scale services, back-end medical support, rater training, and endpoint assessment for international multi-center clinical trials, making clinical trial endpoints more precise.
EClinCloud CEO Dr. Qin Long said: "Empowering new drug R&D through technological innovation is an important part of the EClinCloud team's DNA. The digitalization and intelligentization of clinical research will continue to propel and accelerate the new drug R&D process and bring more opportunities to the industry. Following this round of financing, the company will further increase investment in platform R&D, medical and scientific support, and after-sales service and operations and maintenance. We firmly believe that high-quality platform products and high-value-added services are the foundation of EClinCloud's development."
Dai Yiren, Partner at Kangjun Capital, said: "We are honored to participate in this round of financing. Kangjun Capital focuses on investments in the biopharmaceutical sector, with particular attention to biopharmaceutical R&D services and technology innovation platforms worldwide. EClinCloud's founding team has deep experience in the digital transformation of clinical research and a profound understanding of industry pain points; the design of its integrated platform is innovative, forward-looking, and open, and has already earned recognition within the industry. With a promising future ahead, we hope to work together with EClinCloud to accelerate the integration of more high-quality resources and talent and help clients with their innovative drug development."
About EClinCloud
With the mission of "bringing effective treatments to patients through technological innovation," EClinCloud is a healthcare and life sciences technology enterprise rooted in China and serving the world. We provide a unified, integrated cloud platform along with clinical trial endpoint assessment technologies across therapeutic areas, building a globally leading "patient-centered" clinical evidence support SaaS cloud platform to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency and accelerate the market launch of drugs/devices, benefiting countless patients.
About Kangjun Capital
Kangjun Capital was founded in 2019, focusing on equity investments in the biopharmaceutical sector. Drawing on a distinctive industry perspective and extensive experience across industry, scientific research, management, and capital markets, the Kangjun Capital team invests globally, focusing primarily on globally leading biopharmaceutical R&D service and technology innovation platforms, biotechnology companies, and medical device companies, among others. Kangjun Capital is committed to serving as a bridge connecting the life sciences, the healthcare industry, and capital, and as a trusted long-term partner.


